ArticleNature immunology2024
IL-23 stabilizes an effector T
Open access · hybridAbstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 49 citations in OpenAlex.
- Glutamine metabolism in health and disease.Signal transduction and targeted therapy · 2026Review
- IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4Journal for immunotherapy of cancer · 2026Article
- Bap1-mediated deubiquitination determines immune tolerance and anti-tumor immunity via modulating eTreg cell differentiation and ferroptosis.Cell death and differentiation · 2026Article
- Progress in the development of cytokine armoured CAR T cells.Nature reviews. Immunology · 2026Review
- Inflammatory monocytes constrain YAP-induced cell proliferation.Science advances · 2026Article
- Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026Review
- Inflame and restrain - the paradoxical roles of IL-12 and IL-23 in immunity.Nature reviews. Immunology · 2026Review
- Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset.bioRxiv : the preprint server for biology · 2026Article
- Spatially decoding genotype-associated epigenetic landscapes in human lymphoma FFPE tissues via epi-Patho-DBiT.Nature communications · 2026Article
- Article
- Targeting tumor-associated macrophages through phytochemicals: a promising strategy for cold tumor therapy.Chinese medicine · 2026Review
- IL-23 as a potential mediator of immune evasion and therapeutic target in laryngeal squamous cell carcinoma.BMC cancer · 2026Article
- Cytokines Associated with Activation of CD4International journal of molecular sciences · 2026Review
- Targeting STAT3 Promotes Tumor Cell Death and Enhances T-Cell Activity in HPV16-Positive Cancer.Cancers · 2026Article
- Obstacles and improvement strategies for CAR-T cell therapy in solid tumors.Discover oncology · 2026Review
- Insights into the mechanisms of drug resistance in renal cell carcinoma: from multi-omics perspective.International journal of surgery (London, England) · 2026Article
- In situ self-assembled cell reservoir hydrogel for maneuvering multistage radioimmunotherapy.Nature communications · 2026Article
- Association of copy number alterations with the immune transcriptomic landscape in cancer.NPJ systems biology and applications · 2026Article
- Tumor-associated macrophages in cancer: from mechanisms to application.Molecular biomedicine · 2025Review
- Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications.Molecular biomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 5 institutions in 4 countries.
Tobias Wertheimer *Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Pascale Zwicky *Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Lukas RindlisbacherDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Colin SparanoDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-0776-6896
Marijne VermeerDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Bruno Marcel Silva de MeloDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Claudia HaftmannDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Tamina RückertDepartment of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
Aakriti SethiDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Stefanie SchärliDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-9125-9445
Anna HuberDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Florian IngelfingerDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Caroline XuDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0002-3728-656X
Daehong KimDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Philipp HäneDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
André Fonseca da SilvaDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-2657-7660
Andreas MuschaweckhInstitute for Experimental Neuroimmunology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-6870-1378
Nicolas NunezDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-3837-270X
Sinduya KrishnarajahDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-2348-1751
Natalie KöhlerDepartment of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-7502-0431
Robert ZeiserDepartment of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0001-6565-3393
Mohamed OukkaDepartment of Immunology, University of Washington, Seattle, WA, USA.
Thomas KornInstitute for Experimental Neuroimmunology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-3633-0955
Sonia TuguesDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. tugues@immunology.uzh.ch.ORCID http://orcid.org/0000-0003-1206-3386
Burkhard BecherDepartment of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. becher@immunology.uzh.ch.ORCID http://orcid.org/0000-0002-1541-7867
University of Zurich · CHUniversity of Freiburg · DETUM Klinikum · DEUniversidade de São Paulo · BRUniversity of Washington · US
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) 872/4-1Deutsche Forschungsgemeinschaft (German Research Foundation) SFB1054-B06 (ID 210592381)Deutsche Forschungsgemeinschaft (German Research Foundation) SFB1160 TP B09Deutsche Forschungsgemeinschaft (German Research Foundation) TRR128-Z02 (ID 213904703)Deutsche Forschungsgemeinschaft (German Research Foundation) TRR355 (ID 490846870)Deutsche Forschungsgemeinschaft (German Research Foundation) Walter Benjamin FellowshipGemeinnützige Hertie-Stiftung (Hertie Foundation) EXC 2145 (SyNergy, ID 390857198)Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 310030_188450Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 733 310030_170320Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) PR00P3_179775
Abstract
Interleukin-23 (IL-23) is a proinflammatory cytokine mainly produced by myeloid cells that promotes tumor growth in various preclinical cancer models and correlates with adverse outcomes. However, as to how IL-23 fuels tumor growth is unclear. Here, we found tumor-associated macrophages to be the main source of IL-23 in mouse and human tumor microenvironments. Among IL-23-sensing cells, we identified a subset of tumor-infiltrating regulatory T (T
Indexed as
Interleukin-23NeoplasmsAnimalsCytokinesHumansMiceT-LymphocytesTumor MicroenvironmentCytokinesInterleukin-23
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.